What is the appropriate management of hyperkalemia?

Management of Hyperkalemia

For acute hyperkalemia with ECG changes or severe elevation (K+ >6.5 mEq/L), immediately administer IV calcium gluconate 10 mL of 10% solution to stabilize cardiac membranes, followed by IV insulin (10 units) with dextrose (50 mL) and nebulized salbutamol (20 mg in 4 mL) to shift potassium intracellularly. 1

Acute Hyperkalemia Management

Immediate Cardiac Membrane Stabilization

• IV calcium gluconate (10 mL of 10% solution) acts within 1-3 minutes to reduce membrane excitability and prevent cardiac arrhythmias, though it does not lower serum potassium levels 1
• If no ECG improvement occurs within 5-10 minutes, repeat the calcium dose 1
• In cardiac arrest, use calcium chloride 10 mL instead of calcium gluconate for more rapid effect 2

Intracellular Potassium Shift (Acts in 30-60 minutes)

• IV insulin 10 units with 50 mL dextrose promotes potassium redistribution into cells but does not eliminate total body potassium 1
• Recent evidence suggests lower insulin doses may be optimal to reduce hypoglycemia risk 3
• Nebulized salbutamol 20 mg in 4 mL provides additional intracellular shift with short duration of effect (2-4 hours) 1
• Monitor glucose serially and administer dextrose as needed to prevent hypoglycemia 1

Potassium Elimination

• IV sodium bicarbonate should be reserved for patients with concurrent metabolic acidosis, as it promotes urinary potassium excretion through increased distal sodium delivery 1
• Loop or thiazide diuretics in hypervolemic, non-oliguric patients to enhance urinary potassium excretion 1
• Hemodialysis for patients with oliguria, end-stage renal disease, or refractory hyperkalemia after other interventions 1, 4

Critical Monitoring

• Obtain ECG to assess for peaked T waves and prolonged QRS complexes, though ECG changes are highly variable and not as sensitive as laboratory testing 1
• Rule out pseudohyperkalemia from hemolysis, repeated fist clenching, or poor phlebotomy technique before initiating treatment 1
• Monitor potassium trajectory, ECG changes, and symptoms continuously 1

Chronic Hyperkalemia Management

First-Line Interventions

• Identify and remove reversible causes: discontinue NSAIDs, potassium supplements, and other hyperkalemia-inducing medications when possible 1, 4
• Loop or thiazide diuretics promote urinary potassium excretion by stimulating flow and delivery to renal collecting ducts, but effectiveness depends on residual kidney function 1

Potassium Binders for Long-Term Management

The newer potassium binders (patiromer and sodium zirconium cyclosilicate) are preferred over sodium polystyrene sulfonate for chronic management, as they allow continuation of RAASi therapy while effectively lowering potassium. 1, 5

Sodium Zirconium Cyclosilicate (SZC)

• Highly selective for potassium with rapid onset of action (1 hour) 1
• Acts in both small and large intestines 1
• Dosing: 10 g three times daily for 48 hours for initial correction, then 5 g every other day to 15 g daily for maintenance 1
• Contains 400 mg sodium per 5-g dose 1
• Most common adverse effects: GI disorders (constipation, diarrhea, nausea, vomiting) and mild to moderate edema 1

Patiromer

• Binds potassium in exchange for calcium in the colon with onset of action at 7 hours 1
• Dosing: 8.4 g once daily, titrate up to 16.8 g or 25.2 g daily 1
• Contains 1.6 g calcium per 8.4-g dose but no sodium 1
• Most common adverse effects: GI disorders (abdominal discomfort, constipation, diarrhea, nausea, flatulence) and hypomagnesemia 1

Sodium Polystyrene Sulfonate (SPS) - Use with Caution

• Associated with serious adverse events including intestinal ischemia, colonic necrosis, and 33% mortality rate in some reports 1
• Nonselective binding causes hypocalcemia and hypomagnesemia 1
• Lacks high-quality evidence for long-term efficacy with only one small 7-day randomized trial 1
• Variable onset of action (hours to days) with inconsistent short-term efficacy 1

RAASi Optimization Strategy

Maximum RAASi therapy should be maintained when indicated, as discontinuation increases mortality and major adverse cardiovascular events. 1

• After acute hyperkalemia resolves, reassess potassium within 1 week and consider reinitiation of RAASi therapy 1
• Use newer potassium binders (patiromer or SZC) to facilitate continuation and optimization of RAASi therapy in patients with recurrent hyperkalemia 1
• Monitor serum potassium 7-10 days after starting or increasing RAASi doses 1
• Discontinuation of RAASi in patients with eGFR <30 mL/min/1.73 m² is associated with higher mortality risk compared to continuation 1

Monitoring Frequency

• Individualize monitoring based on risk factors: more frequent testing for patients with CKD, diabetes, heart failure, history of hyperkalemia, or those taking RAASi 1
• Plasma potassium concentrations are typically 0.1-0.4 mEq/L lower than serum levels due to platelet release during coagulation 1

Common Pitfalls to Avoid

• Do not rely solely on ECG findings to diagnose or exclude hyperkalemia, as changes are highly variable and nonspecific 1
• Avoid fludrocortisone for chronic management due to increased risk of fluid retention, hypertension, and vascular injury 1
• Do not use sodium polystyrene sulfonate as first-line chronic therapy given serious GI complications and lack of efficacy data 1, 2
• Avoid discontinuing RAASi therapy without attempting potassium management strategies first, as this increases cardiovascular and renal morbidity/mortality 1, 5
• Do not administer potassium binders simultaneously with other oral medications, as they may bind and reduce absorption 1